|
CN104583189A
|
|
Amorphous cabazitaxel
|
|
US2007142449A1
|
|
Angiogenesis inhibitors
|
|
TW200732305A
|
|
Cancer chemotherapy
|
|
US2008146541A1
|
|
Method of treating symptoms of hormonal variations
|
|
KR20060043654A
|
|
Preferential inhibition of release of pro-inflammatory cytokines
|
|
JP2005118051A
|
|
NEW SACCHAROTHRIX STRAIN, METHOD FOR PRODUCING PRAVASTATIN BY USING THE SAME AND METHOD FOR ISOLATING (HMG)-CoA REDUCTASE
|
|
US2005215612A1
|
|
Fused pyrazolyl compound
|
|
KR20050041184A
|
|
Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
|
|
KR20040057377A
|
|
Treatment of disorder related to low cyclic gmp levels
|
|
US7166641B2
|
|
Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
|
|
US6902746B2
|
|
Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
|
|
US6699892B2
|
|
Pharmaceutically acceptable salt of amlodipine and method of preparing the same
|
|
EP1270008A2
|
|
Fused tricyclic analogues of guanosine for treating tumors
|
|
US6716615B2
|
|
Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase
|
|
JP2003250532A
|
|
NEW SACCHAROTHRIX STRAIN, METHOD FOR PRODUCING PRAVASTATIN WITH THE SAME, AND METHOD FOR ISOLATING (HMG)-CoA REDUCTASE
|
|
US6518294B2
|
|
Fused pyrazolyl compounds
|
|
EP1420023A1
|
|
Use of fused pyrazolyl compounds for the preparation of a medicament for treating hypertension
|
|
US6387942B2
|
|
Method of treating disorders related to protease-activated receptors-induced cell activation
|
|
KR20020066832A
|
|
Fused pyrazolyl compounds
|
|
US6306435B1
|
|
Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
|
